Seaport and Hemab Complete $600 Million Nasdaq IPO to Fund SPT-300 and Sutacimig Clinical Programs
Nasdaq IPO Market Momentum and Dual Listings
Amid a strong recovery in the spring 2026 biotech IPO market, neuropsychiatric‑focused company Seaport Therapeutics (ticker: SPTX) and rare‑blood‑disorder‑focused company Hemab Therapeutics (ticker: COAG) simultaneously secured listings on the New York Stock Exchange. Seaport (SPTX) raised $254.9 million at $18.00 per share, while Hemab (COAG) attracted $346.7 million, including an overallotment option. The dual listings acted as a catalyst for Nasdaq biotech companies to raise a total of $3.2 billion in 2026, underscoring a renewed risk‑on sentiment among investors in the sector.
Seaport’s Lymphatic Bypass Platform and Depression Therapeutic Innovation
Seaport (SPTX) is developing SPT‑300 (GlyphAllo), a prodrug of allopregnanolone that acts as a positive allosteric modulator of the GABA‑A receptor for the treatment of Major Depressive Disorder (MDD). While existing agents rely on intravenous administration due to first‑pass metabolism constraints, Seaport’s proprietary Glyph Platform enables oral delivery. The program is currently in a global Phase 2b trial with readout expected in the first half of 2027. With the global antidepressant market exceeding $10.5 billion in 2023, an orally administered therapy that markedly improves convenience could be a market‑changing game‑changer.
Hemab’s Bispecific Antibody Approach for Rare Hemorrhagic Disease Prevention
Hemab (COAG) is advancing sutacimig (HMB‑001), a bispecific antibody targeting Glanzmann Thrombasthenia (GT), through combined Phase 1/2 studies. Sutacimig stabilizes endogenous Factor VIIa and simultaneously engages the platelet‑expressed TLT‑1 (TREM‑like transcript‑1) receptor, promoting hemostasis. Currently, no approved prophylactic therapy exists for GT; patients rely on transfusions or post‑event administration of recombinant activated Factor VIIa products such as NovoNordisk’s NovoSeven. Sutacimig has received Breakthrough Therapy Designation from the U.S. FDA and is expected to shift the treatment paradigm toward primary prevention.
Accelerated Clinical Development and Share‑Price Upside Expectations
The listings were enabled by the companies’ differentiated technology barriers and early clinical success, which were highly valued by investors. Seaport will allocate proceeds to complete the Phase 2b trial of SPT‑300 and to advance its next‑generation candidate SPT‑320. Hemab will intensify the clinical development of sutacimig and launch the HMB‑002 program. Robust capital positions give both firms leverage in licensing negotiations with global big‑pharma partners. Public‑market investors are focusing on the upcoming trial readouts as potential catalysts for strong share‑price appreciation.
Seaport (SPTX) and Hemab (COAG) jointly raising $600.16 million in a simultaneous Nasdaq IPO marks a short‑term milestone signaling the thaw of the biotech IPO market and, in the medium to long term, a catalyst for accelerating technological progress in markets with high unmet medical need. From an investor perspective, the Phase 2b data for SPT‑300 in Major Depressive Disorder expected in early 2027 and the Phase 1/2 results for sutacimig (HMB‑001) will be key drivers of future share‑price gains and valuation re‑rating. Drug researchers will be inspired by Seaport’s lymphatic absorption platform that overcomes first‑pass metabolism and Hemab’s bispecific antibody that targets both TLT‑1 and Factor VIIa, expanding the frontier of insoluble drug delivery and targeted hemostasis design. For industry participants, the robust clinical pipeline provides sufficient R&D ammunition to compete with entrenched players such as Sage Therapeutics’ Zurzuvae or Novo Nordisk’s NovoSeven in the $10.5 billion depression market and the rare hemorrhagic disease space, enhancing licensing negotiation leverage and generating positive spill‑over effects including new job creation.
Source: BioPharma Dive (rss)
https://www.biopharmadive.com/news/seaport-hemab-ipo-price-biotech-2026/818965/